Fosun Highlights Global Innovation and AI Initiatives at Sustainability Leaders Conference

Fosun International outlined its innovation-led global strategy at the 2025 Sustainability Global Leaders Conference in Shanghai, announced in a press release. Co-Chairman Wang Qunbin presented the company’s achievements in biotechnology, digital transformation, and sustainable development.

Wang highlighted the success of HANSIZHUANG, the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer. The drug has received approval in nearly 40 countries and regions, including China, the EU, and the UK. He also noted that its Phase III clinical trial for perioperative gastric cancer recently met its primary endpoint, supporting future market approval.

Fosun’s biopharmaceutical division has expanded global research and development capabilities, with products reaching nearly 60 countries and regions. The company has built platforms for small and large molecule drugs, cell therapy, and nuclear medicine, while establishing partnerships with Abbott, Dr. Reddy’s, Lotus, and Sandoz. In the first half of 2025, its licensing and business development activities generated over RMB1 billion.

Beyond pharmaceuticals, Fosun Tourism Group advanced AI-driven customer experiences through a collaboration with Alibaba Cloud to develop the “AI G.O” cultural tourism system based on Tongyi Qianwen models. AI applications have also been introduced in Fosun Insurance Portugal, increasing the automation rate of motor claims processing to 66%.

Fosun’s social responsibility efforts include global malaria treatment initiatives and China’s Rural Doctors Program. Its second-generation artesunate injection, Argesun, received WHO prequalification in 2023, improving treatment accessibility in remote areas. The company also launched an AI Rural Doctor Assistant powered by Alibaba’s large model to support healthcare in rural China.